Stallergenes' 1st-half 2007 profit rises 32%

French specialist allergy drug developer Stallergenes has reported an improvement in its financial performance, with net profits for the first six months of 2007 up 32% on the comparable period last year, to 10.1 million euros ($13.7 million).

During the period, sales rose 17% to 74.8 milllion euros, directly in line with the increase in gross profit, which totaled 57.9 million euros. According to the firm, operating profit, up 26%, fully benefited from the sharp growth in sublingual route sales, which rose 21%, a segment in which Stallargenes consolidated its leadership and strategic positioning. In the first six months of the year, the firm saw the incorporation of Stallergenes BV in Holland, as well as active preparation of the Orolair grasses tablet registration in Canada.